At the news
? NEUTRALIMPACT 1/10 3 filed Nov 12, 2026 at 16:00 ET
Aaron Ondrey filed a Form 3 initial statement of beneficial ownership after becoming Chief Financial Officer of Syndax Pharmaceuticals. The filing reports no securities owned and is a routine compliance document with no trading or financial impact.
- Aaron Ondrey appointed Chief Financial Officer of Syndax Pharmaceuticals Inc.
- Form 3 filed on 2026-11-12, reporting period 2026-11-09.
- No securities ownership reported in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access